Skip to content

Bioalmanac

PE-22-28

Mini-spadin · Spadin analogue

Preclinical

Status reviewed 18 Aug 2026

A spadin-derived peptide targeting a potassium channel. A genuinely novel antidepressant mechanism, demonstrated in mice and nowhere else.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Nasal solutions are handled more than injectables and are correspondingly easier to contaminate.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 10 mg vial, 500 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL10 mg/mL0.05 mL5 units20
2 mL5 mg/mL0.1 mL10 units20
3 mL3.333 mg/mL0.15 mL15 units20
5 mL2 mg/mL0.25 mL25 units20

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly described community protocol200–800 mcgOnce daily, often in short coursesCommunity practice

When to stop

  • Worsening mood, agitation, or any thought of harming yourself. Seek help immediately.
  • Palpitations or an irregular heartbeat.
  • Any new neurological symptom, including seizure activity.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Not approved anywhere and never studied in a human trial. Developed in academic research; no clinical programme has reported. Sold only as a research chemical.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/pe-22-28

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.